AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026

Phase 2 zumilokibart data in adults with atopic dermatitis met the primary endpoint across all three dose regimens, delivering significantly higher EASI-75 response rates than placebo at Week 16. The company selected the mid-dose regimen for further development, supporting progression of the dermatology pipeline.